...
首页> 外文期刊>Oncology letters >Detection of urinary survivin using a magnetic particles-based chemiluminescence immunoassay for the preliminary diagnosis of bladder cancer and renal cell carcinoma combined with LAPTM4B
【24h】

Detection of urinary survivin using a magnetic particles-based chemiluminescence immunoassay for the preliminary diagnosis of bladder cancer and renal cell carcinoma combined with LAPTM4B

机译:使用磁性颗粒的化学发光免疫测定检测尿素存活蛋白,用于膀胱癌和肾细胞癌的初步诊断与LabeM4B相结合

获取原文
获取原文并翻译 | 示例

摘要

The aim of the present study was to establish a simple step magnetic particles (MPs) based chemiluminescence enzyme immunoassay (CLEIA) for the detection of urinary survivin, and to investigate the diagnostic value of urinary survivin and lysosome-associated protein transmembrane-4 beta (LAPTM4B) in bladder cancer (BC) and renal cell carcinoma (RCC). The MPs-based CLEIA was developed on the basis of a double antibodies sandwich immunoreaction and luminol-H2O2 chemiluminescence system. The parameters of the method were optimized and evaluated. Urine samples were obtained from 200 BC patients, 81 RCC patients and 114 healthy individuals, and the MPs-based CLEIA method was employed to detect their urinary survivin. At the same time, the urinary LAPTM4B levels of the BC patients, RCC patients and the healthy controls were measured. The diagnostic efficiency of urinary survivin and LAPTM4B in BC and RCC was evaluated separately and jointly. A one-step MPs-based CLEIA for the detection of urinary survivin with good accuracy and precision was established. The signals were dependent on survivin concentrations in the range, 0 to 200 ng/ml, and the detection limit was 0.949 ng/ml. The areas under the receiver operating characteristic curves (AUC) were 0.771 in BC and 0.763 in RCC for urinary survivin. Urinary survivin was correlated with the tumor stage (P=0.002), lymph node metastasis (P=0.017), distant metastasis (P=0.005) and tumor size (P=0.02) of BC; however, no association with the clinicopathological parameters in RCC was observed. The AUCs for urinary LAPTM4B were 0.738 in BC and 0.704 in RCC, respectively. The AUCs for them combined were 0.842 in BC and 0.920 in RCC. The MPs-based CLEIA was performed well in the detection of urinary survivin. Urinary survivin and LAPTM4B could serve as potential biomarkers for the preliminary diagnosis of BC and RCC, and in combination they a achieved a greater diagnostic performance.
机译:本研究的目的是建立一种简单的步骤磁性颗粒(MPS)的化学发光酶免疫测定(CLEIA),用于检测尿Survivin,并研究尿Survivin和溶酶体相关蛋白跨膜-4β的诊断价值( LaptM4B)在膀胱癌(BC)和肾细胞癌(RCC)中。基于MPS的Cleia是基于双抗体夹层免疫反应和Luminol-H2O2化学发光系统开发的。优化和评估该方法的参数。尿液样本是从200bc患者中获得的,81例RCC患者和114名健康个体,并且使用基于MPS的Cleia方法来检测其尿素。同时,测量了BC患者,RCC患者和健康对照的尿LaptM4B水平。单独和共同评估尿Survivin和LaptM4b尿基因素和Laptm4b的诊断效率。建立了一种以良好的准确度和精度检测尿Survivin的基于一步的基于MPS的克利亚。信号依赖于0至200ng / ml的Survivin浓度,检测限为0.949ng / ml。接收器操作特征曲线(AUC)下的区域在BC的0.771中,在RCC中为0.763,用于泌尿生存素。尿基于肿瘤阶段(P = 0.002),淋巴结转移(P = 0.017),远处转移(P = 0.005)和BC的肿瘤大小(P = 0.02);但是,观察到没有与RCC临床病理参数的关联。泌尿式LaptM4B的AUC分别在BC和0.704的RCC中为0.738。它们的AUC组合在BC和RCC中的0.920℃为0.842。在尿素存活素的检测中表现良好的基于​​MPS的Cleia。尿Survivin和Labtm4b可以作为潜在的BC和RCC初步诊断的潜在生物标志物,并且在组合中,他们实现了更大的诊断表现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号